Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

February 8, 2021February 8, 2021

‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer

News

After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative oral therapy Endoxifen in women newly diagnosed with invasive, estrogen ... Read more

January 25, 2021January 25, 2021

Enhertu Approved in EU for Inoperable, Advanced Breast Cancer

News

The European Commission has conditionally approved Enhertu (trastuzumab deruxtecan) for adults in the EU with inoperable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. ... Read more

January 21, 2021January 21, 2021

Imagio Imaging System for Breast Cancer Diagnosis Approved by FDA

News

Imagio, Seno Medical Instruments’ non-invasive and radiation-free breast imaging technology, has been approved for commercialization by the Center for Devices and Radiological Health, part of the U.S. Food and Drug Administration ... Read more

November 19, 2020November 19, 2020

FDA Approves Keytruda-chemo Combo for Advanced TNBC Positive for PD-L1

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), in combination with chemotherapy, to treat people with advanced triple-negative breast cancer (TNBC) and at least 10% of tumor cells ... Read more

February 19, 2020February 19, 2020

Tucatinib Granted FDA Priority Review for Advanced HER2-positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Seattle Genetics’ application seeking approval of its investigational therapy tucatinib, in combination with trastuzumab and Xeloda (capecitabine), for treating people with locally advanced inoperable or metastatic HER2-positive breast cancer. This ... Read more

January 13, 2020January 13, 2020

Certain Genomic Tests May Soon Be Reimbursable for Breast Cancer Patients in Germany

News

Techniker Krankenkasse, one of the largest healthcare insurers in Germany, will begin reimbursing their breast cancer patients for genomic tests, announced Agendia, a diagnostics company that offers a test called MammaPrint. ... Read more

December 30, 2019January 6, 2020

Seattle Genetics Seeks Tucatinib’s Approval by FDA for Advanced HER2-positive Breast Cancer

News

Seattle Genetics has submitted an application requesting U.S. Food and Drug Administration (FDA) approval for its investigational therapy tucatinib, in combination with trastuzumab and Xeloda (capecitabine), for treating people with locally advanced ... Read more

December 18, 2019January 15, 2020

TAVO Boosts Responses to Keytruda in Triple-negative Breast Cancer Patients, Interim Phase 2 Data Show

News

Treatment with TAVO (intratumoral IL-12) appears to increase the sensitivity of previously treated advanced triple-negative breast cancers (mTNBC) to the immune checkpoint inhibitor Keytruda (pembrolizumab), interim data from a Phase ... Read more

November 9, 2018

Researchers Develop ‘Bio-patch’ to Monitor Post-surgical Success of Breast Reconstruction

News

An international team of researchers has developed a wireless device that can detect early problems after a patient undergoes breast reconstruction surgery. The work, led by Imperial College London in the U.K., ... Read more

November 2, 2018

Processed Meat Consumption Linked to Higher Breast Cancer Risk, Review Study Shows

News

Eating processed meat, such as sausage, ham, and bacon, but not red meat, on a regular basis is associated with a significantly increased risk of breast cancer, a review study ... Read more